Humanigen Inc

+0.06 (+2.15%)
: $2.85 0.00 (0.00%)
Products, Earnings Announcements

Humanigen Aligns With FDA On Potential Registration Phase 3 Study For Lenzilumab With CAR-T

Published: 01/10/2022 11:52 GMT
Humanigen Inc (HGEN) - Humanigen Aligns With FDA on Potential Registration Phase 3 Study for Lenzilumab With Car-t.
Humanigen Inc - Shield Trial Will Build on Positive Results From Zuma-19 Study.
Humanigen Inc - Randomized, Double-blind, Placebo-controlled Shield Trial to Commence in H1 2022.
Humanigen - Primary Endpoint of Shield Will Focus on Demonstrating a Significant Improvement in Neurotoxicity Associated With Both Yescarta & Tecartus.
Humanigen Inc - Will Also Seek to Demonstrate Beneficial Impact That Lenzilumab May Have on Healthcare Resource Utilization.
Humanigen Inc - Shield Study Will Begin Recruitment in H1 2022, With Prelim Data Potentially Being Shared in December 2022.
Revenue is expected to be $0.36 Million
Adjusted EPS is expected to be -$0.65

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.